Amid sweeping changes in the global healthcare landscape, Taiwan’s medical and wellness industries have shown exceptional resilience and competitiveness as they pursue international breakthroughs. At the 2025 IBMI Annual Conference, Vice Chairman Tsai Chang-hai presented the 2024 Benchmark Enterprise Award to the Taiwanese company that best exemplified innovation and global impact over the past year.

Tsai explained that the Benchmark Enterprise Award honors outstanding achievements in three key areas:

1. International Licensing Benchmark

   • Requires cumulative licensing revenue of at least USD 100 million, with a minimum of USD 10 million recognized in the award year.

2. R&D Breakthrough Benchmark

   • Recognizes innovative products targeting major global diseases that have either secured market approval in at least two of the U.S., EU, or Taiwan during the award year, or completed global Phase III clinical trials.

3. Major Investment Benchmark

   • Celebrates large-scale investments—such as new facility builds, expansions, or M&A—totaling at least USD 200 million in the award year.

The sole 2024 awardee was Bora Pharmaceuticals, which excelled in the Major Investment category. Founded in 2007 as a pharmaceutical manufacturing service provider, Bora embarked on significant international expansion in 2024, acquiring two U.S. companies and a sterile injectable plant, with total investments of USD 267 million—underscoring Taiwan’s capacity for global market deployment.

Notably, no companies met the criteria for the International Licensing or R&D Breakthrough awards in 2024. Tsai Chang-hai observed that intensifying international competition demands Taiwanese technology firms accelerate their innovation and R&D efforts to seize first-mover advantage on the world stage.